Page 56 - Practice Guidelines News Today

Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab) two very rare forms of non-Hodgkin lymphoma will not have access to an innovative systemic treatment following NICEs decision to not recommend mogamulizumab for routine use in the NHS . Kyowa Kirin is disappointed by this decision but remains committed to finding a resolution with NICE. The National Instit...

Share this article Share this article SAN FRANCISCO, March 3, 2021 /PRNewswire/ -- Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Notes pipeline assets. The Series A financing was led...

Mineral and Financial Investments Limited Investment Update: Redcorp Increases M&I Resources By 44% & Inferred Resources By 21% At Lagoa Salgada South Zone   HIGHLIGHTS: · Measured and Indicated Resource Estimate increased by 44% to 4.4Mt at 1.51% CuEq[1] Inferred Resource increased 21% to 7.7 Mt at 1.41% CuEq 1 · Demonstrates significant growth from successful Phase 1 drill program · Phase II drill program underway to ex...

AstraZeneca and FibroGen, Inc. (FibroGen) today announced that the US Food and Drug Administration (FDA) informed FibroGen that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new drug application for roxadustat. Roxadustat is under regulatory review for the treatment of anaemia of chronic kidney disease (CKD). AstraZeneca and FibroGen are committed to working with the FDA ahead of the meeting and to bringing roxadustat to patients with anaemia o...

Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant USA - English Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard...

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant - Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient populati...

® for Histiocytosis. Histiocytoses are rare disorders characterized by a buildup of white blood cells called histiocytes, which leads to tissue damage. This group of disorders is diagnosed in a few thousand people every year across the United States. As a result of this low incidence rate, people are often diagnosed late and receive treatment from doctors who have limited or no prior experience with the disease. These new clinical practice guidelines from NCCN provide the latest evidence and e...

(1) EUSA Pharma (UK) Limited (" EUSA Pharma"), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network (NCCN ) for B-Cell Lymphomas to include siltuximab (SYLVANT ) as the preferred primary treatment for patients with human immunodeficiency virus-negative [HIV(-)] and human herpesvirus 8-negative [HHV-8(-)] multicentric Castleman disease (MCD), also known as idiopathic multicentric Castleman disease (iMCD), regardless of...

On January 14, 2021, days before a change in presidential administrations, the US Department of Health and Human Services (HHS) announced a plan to publish Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder “pursuant to 21 USC §823(g)(2)(H)(i)(II),” a provision of the Drug Addiction and Treatment Act of 2000 (DATA 2000). 1 This announcement caused a mix of enthusiasm, skepticism, and confusion in the medical community, and the retraction of the pla...

Leading Health and Cancer Advocacy Groups Unite to Reduce Racial Disparities in Cancer Care USA - English News provided by Share this article ®), American Cancer Society Cancer Action Network (ACS CAN) and the National Minority Quality Forum (NMQF) presented new ideas for overcoming inequality in oncology. The recommendations—developed by a group of 17 national experts, representing patients and advocates, caregivers, healthcare providers, researchers, and industry—directly address how med...